Albicidin Derivatives for Antibacterial Activity and Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing albicidin derivatives face challenges with poor solubility, bioavailability, and resistance to bacterial efflux systems, limiting their effectiveness as broad-spectrum antibiotics.
Innovation Solution
Development of novel albicidin derivatives with specific molecular structures, including substituted or unsubstituted bicyclic systems and aromatic heterocycles, to enhance solubility and bioavailability, and incorporate features like cyclodextrins for improved solubility, allowing for various administration forms and formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If albicidin derivatives with high lipophilicity are designed to improve membrane penetration, then antibacterial activity is enhanced, but solubility decreases and plasma protein binding increases
Solution Approach 1:
The patent systematically modifies molecular parameters including clogP (lipophilicity), molecular weight, and polar surface area to optimize the balance between membrane penetration and solubility. By controlling these parameters within specific ranges, the derivatives achieve improved antibacterial activity while maintaining adequate solubility properties
Solution Approach 2:
The patent introduces specific functional groups and structural modifications at particular positions of the albicidin core structure. These localized changes affect specific properties such as lipophilicity and hydrogen bonding capacity, allowing fine-tuning of the overall pharmacological profile without completely redesigning the molecule
2Reliability
If albicidin derivatives with high lipophilicity are designed to improve membrane penetration, then antibacterial activity is enhanced, but plasma protein binding increases reducing active drug
Solution Approach 1:
The patent optimizes the lipophilicity parameter (clogP) within a specific range to achieve sufficient membrane penetration while limiting excessive plasma protein binding. This parameter control ensures that enough unbound active drug remains available to exert antibacterial effects
3Quantity of substance
If albicidin structure is modified to improve solubility by increasing polarity, then solubility is enhanced, but membrane penetration ability decreases
Solution Approach 1:
The patent carefully controls the polar surface area and hydrogen bonding capacity within optimal ranges. This allows the derivatives to achieve improved solubility while maintaining sufficient lipophilicity for membrane penetration, resolving the contradiction between these two properties
4Duration of action of stationary object
If molecular size is increased to improve pharmacokinetic properties, then metabolic stability is enhanced, but bioavailability decreases
Solution Approach 1:
The patent optimizes molecular weight within a specific range, avoiding excessive molecular size that would hinder absorption while ensuring sufficient metabolic stability. This balanced approach maintains both bioavailability and metabolic stability
Data Source
AI summary
Please cancel the abstract of this application and replace it with the following amended abstract presented in clean form according to the procedures outlines in MPEP 714(II)(B):It is provided a chemical compound according to general formula (1)